Clinical trials: Dextrose Concentration
PreDiabetes, Impaired Fasting Glucose (IFG)
Metformin and Its Impact on the Substances Associated With NO Production in Prediabetes Patients.
This study evaluates the effect of different doses of metformin on the function of endothelium in people with pre-diabetes. One group of the patients will receive metformin in dose: 1500 mg, the second one will receive 3000…
- Conditions
- PreDiabetes, Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT)
- Trial name
- NCT03398356
- Testing
- Metformin
- Where
- Poland
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Wroclaw Medical University
Type 2 Diabetes Mellitus
A Study of the Effects of Co-Administration of Sitagliptin (MK-0431) and Metformin on Incretin Hormone Concentrations (MK-0431-110)
This study will assess the effects of sitagliptin and metformin alone and after co-administration on incretin hormone concentrations in patients with Type 2 diabetes.
- Trial name
- NCT00830076
- Testing
- sitagliptin phosphate, metformin hydrochloride
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Polycystic Ovary Syndrome
Effects of Flutamide on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome
Polycystic Ovary Syndrome (PCOS) is the major cause of infertility in the United States. Many women with PCOS demonstrate insulin resistance and a compensatory hyperinsulinemia.This is due to both an intrinsic form of insulin…
- Trial name
- PCOS (NCT00729560)
- Testing
- Flutamide
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Virginia Commonwealth University
Type II Diabetes Mellitus
SGLT2 Inhibition and Stimulation of Endogenous Glucose Production: Protocol 2
In Protocol 2, the investigators will determine the role of pancreatic hormones (increase in plasma glucagon and decrease in plasma insulin concentration) in the stimulation of EGP following SGLT2 inhibition.
- Trial name
- NCT02592421
- Testing
- Dapagliflozin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type II Diabetes Mellitus, Renal Insufficiency
A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated
A study to look at the effect MEDI0382 has on blood sugar in people with type 2 diabetes and kidney problems and also to check that MEDI0382 is well tolerated.
- Trial name
- NCT03550378
- Testing
- MEDI0382
- Where
- 7 sites in Germany, United Kingdom
- Volunteers
- 41 people
- Sponsor
- MedImmune LLC
Type 2 Diabetes Mellitus
An Investigational Drug Study in Adults With Type 2 Diabetes on Basal Insulin (MK-0941-006)
A study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of MK-0941 in Type 2 diabetics being treated with basal insulin.
- Trial name
- NCT00511472
- Testing
- MK-0941, LANTUS insulin
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Assessing the PK and Effect on Glucose and GI Hormone Concentrations of Metformin Delayed-Release in Subjects With T2DM
This study will evaluate how EFB0027 and EFB0026 behave in subjects with type 2 diabetes mellitus. In addition, this study will compare the effects of EFB0027 and EFB0026 on circulating concentrations of glucose and…
- Trial name
- NCT01677299
- Testing
- EFB0027 (metformin delayed release), EFB0026 (metformin immediate-release)
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Elcelyx Therapeutics, Inc.
Healthy Subjects
A Safety Study to Assess the Effects of Therapeutic and Supratherapeutic Exenatide Concentrations on QT Interval in Healthy Subjects
Compare the effect of exenatide (therapeutic and supratherapeutic concentrations), moxifloxacin and placebo on the QT interval.
- Trial name
- NCT01297062
- Testing
- Exenatide, Moxifloxacin
- Where
- 2 sites in United States
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Type 2 Diabetes
The Effect of Welchol on Glucose Metabolism in Type 2 Diabetics
The goal of this study was to determine the metabolic mechanism for a certain type medication's ability to lower blood sugar after a meal in Type 2 Diabetics, in order to develop a better understanding of it's potential role in…
- Trial name
- NCT00951899
- Testing
- Colesevelam, Diet, Metformin
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Polycystic Ovary Syndrome
Effects of Pioglitazone on Insulin and Glucose Metabolism in Women With Polycystic Ovary Syndrome (PCOS)
Our hypothesis is that hyperinsulinemia increases the renal clearance of D-chiro-inositol (DCI) in women with polycystic ovary syndrome (PCOS) and that this leads to a reduction in circulating insulin-stimulated…
- Trial name
- PCOS (NCT00868140)
- Testing
- pioglitazone
- Where
- 2 sites in United States, Venezuela
- Volunteers
- 51 people
- Sponsor
- Virginia Commonwealth University
Diabetes Mellitus, Type II
A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.
LY2189265 is an investigational drug being developed for the treatment of type 2 diabetes mellitus. This study will compare the concentrations of LY2189265 using different methods of administration: subcutaneous (or SC- an…
- Trial name
- NCT01301092
- Testing
- LY2189265
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Insulin Sensitivity
The Effect of TLR4 Inhibition in Obese and Type 2 Diabetic Subjects
To determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) will reduce inflammation and improve glucose metabolism in insulin resistant (obese and T2DM) subjects.
- Trial name
- Eritoran2 (NCT02267317)
- Testing
- Eritoran, D5W
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Cardiovascular Risk Factor, Cardiovascular Diseases
Substituting Sitting With Standing and Walking in Free-living Conditions Improves Daily Glucose Profile in South Asians
The purpose of this study is to investigate the effects of substituting sitting under free-living conditions in South Asian adults with overweight and obesity on continuous glucose profiles.
- Conditions
- Cardiovascular Risk Factor, Cardiovascular Diseases, Diabetes, Type 2 Diabetes
- Trial name
- NCT04645875
- Testing
- SIT regimen, SITless regimen
- Where
- United Kingdom
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- University of Bedfordshire
Diabetes Mellitus, Postprandial Lipemia
Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes
Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated…
- Trial name
- NCT00660075
- Testing
- Sitagliptin
- Where
- Canada
- Volunteers
- 36 people
- Sponsor
- Laval University
Diabetes Type 2
Effect of Dialysis Glucose Bath on Glycemic Control in Hemodialysis (HD)
Background: Type II diabetes is a disease that affects more than 246 million people worldwide. Most importantly, one of the complications of type II diabetes is kidney damage and this has lead to many patients seeking…
- Trial name
- NCT01359904
- Testing
- High Dialysate bath
- Where
- Canada
- Volunteers
- 33 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Diabetes Mellitus, Type 1
A Study of LY2605541 (Insulin Peglispro) and Human Insulin Concentrations in Fat Tissue
LY2605541 is an investigational drug being developed for the treatment of diabetes mellitus. This study is designed to understand how the body handles the investigational drug, and to measure the quantity of LY2605541 in fat…
- Trial name
- NCT02109029
- Testing
- Insulin Peglispro, Human Insulin
- Where
- Austria
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder, Glucose Intolerance
Vyvanse and Glucose Intolerance in Children With Attention Deficit Hyperactivity Disorder (ADHD) and Obesity
The purpose of this study to assess the effects of chronic administration of Vyvanse (lis-dexamphetamine) on glucose metabolism in a sample of children and adolescents with Attention Deficit Hyperactivity Disorder (ADHD) who also…
- Conditions
- Attention Deficit Hyperactivity Disorder, Glucose Intolerance, Obesity
- Trial name
- NCT01017263
- Testing
- Lis-dexamphetamine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Duke University
Schizophrenia, Schizoaffective Disorder
Effect of Single Dose Intranasal Insulin On Cognitive Function
The purpose of the study is to find out how a small dose of insulin might affect memory, the ability to concentrate, and improve your daily functioning in patients with schizophrenia and schizoaffective disorders.
- Trial name
- NCT00646581
- Testing
- Insulin (Humulin)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University of Massachusetts, Worcester
Insulin Sensitivity
The Role of TLR4 on Lipid-induced Insulin Resistance
The purpose of this study is to determine whether pharmacologic inhibition of Toll-like receptor 4 (TLR4) with eritoran for injection (E5564) prevents lipid-induced insulin resistance in lean, normal glucose tolerant (NGT)…
- Trial name
- Eritoran1 (NCT02321111)
- Testing
- Eritoran, D5W (5% Dextrose in water)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center at San Antonio
Type 2 Diabetes Mellitus
Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM
The purpose of this study is to evaluate the pharmacokinetics of Saxagliptin, 5-hydroxy Saxagliptin, and Metformin in pediatric subjects with Type 2 diabetes mellitus (T2DM) following oral administration of Saxagliptin and…
- Trial name
- NCT01525225
- Testing
- Metformin immediate release (IR), Saxagliptin, Metformin IR
- Where
- 7 sites in United States
- Volunteers
- 4 people
- Sponsor
- AstraZeneca